Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration.
Reis GM, Grigg J, Chua B, Lee A, Lim R, Higgins R, Martins A, Goldberg I, Clement CI.
Reis GM, et al. Among authors: lee a.
J Curr Glaucoma Pract. 2017 Jan-Apr;11(1):3-7. doi: 10.5005/jp-journals-10008-1213. Epub 2017 Jan 18.
J Curr Glaucoma Pract. 2017.
PMID: 28138211
Free PMC article.
Secondary outcomes were presence and type of glaucoma, number of injections, and time to IOP elevation. RESULTS: Elevated IOP occurred at a significantly higher rate in eyes receiving IVT ranibizumab (7.47%; n = 9) compared with control (0.93%; n = 1). ...CONCLUSION: Intra …
Secondary outcomes were presence and type of glaucoma, number of injections, and time to IOP elevation. RESULTS: Elevated IOP occurred at …